Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of interleukin-17A inhibitor izokibep (ABY-035) in non-infectious uveitis
2020-004964-25Phase 2Terminated
- Sponsor
- Affibody Medical AB
- Start
- Feb 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of izokibep in uveitis, sponsored by Affibody Medical AB. Primary endpoint: Complete Response at Week 10. Started Feb 2021; status: terminated.
02
Drugs
izokibep
03
Conditions
uveitis
Beyond the preview
Go deeper on 2020-004964-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004964-25.